In the life of a technology company that aims to advance health care, the stage between promise and product can feel less like a runway and more like a tightrope.
The science is encouraging. The founders have left academic labs or hospital posts to turn an idea into a product. But the path forward – through product development, regulatory approval, clinical validation and scaled manufacturing – is long and expensive. And increasingly, traditional sources of funding are wary of stepping in too soon.
At Cornell, a program called Ignite Cornell Research: Lab to Market was designed precisely for that moment.
Managed by Cornell’s Center for Technology Licensing (CTL), Ignite gap funding series is nurturing three early-stage biomed startups that could better detect illnesses, unlock RNA insights to develop new therapies, and improve IVF treatment, among more than a hundred other projects.
Since its founding four years ago, 32 Ignite-supported technology startups have secured significant funding for growth, executed 38 licenses and options and attracted $231 million follow-on funding. This comes as venture capital for deep tech startups has dwindled and government funding for technology translation is uncertain.
“It’s a reality that universities’ technologies usually start at a very early stage,” said Alice Li, executive director of CTL. “We’re focused on getting those discoveries out of the lab and into real-world use and products sooner – at a moment when the public is asking what value universities deliver.”
Ignite’s model recognizes that as investors become more selective, early validation is not a luxury but a prerequisite. By offering hands-on commercialization guidance and funding, the program aims to help startups generate the data and momentum they need to survive the so-called “valley of death” between discovery and market.
